David's Favorites
April 2018
Capricor Therapeutics has announced that researchers found that repeat dosing of the company’s…
Blog Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model 2 FavoritesNovember 2017
PPMD is excited to learn that Capricor's investigational cell therapy, CAP-1002, is showing significant improvements…
Blog Capricor Reports Significant Improvements in Duchenne Patients Treated with CAP-1002 Investigational Cell Therapy 2 FavoritesSeptember 2016
Today, my sons are dancing! Today we ALL celebrate the first…
Blog FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy 3 FavoritesApril 2016
March 2016
At long last we have…
Blog FDA Releases New Date for Eteplirsen Ad Comm 2 FavoritesJanuary 2016
PPMD supported the development of the HT-100 program from early on, including a $500,000 investment via our GIFTED program for the clinical trial. We are excited for…
Blog Akashi Therapeutics Establishes International Partnership with Grünenthal Group on HT-100 for DMD 1 Favorite We did it! Over $270,000 raised to support early-stage research.Last month we told you we hoped to raise $200,000 to…
Blog We did it! Over $270,000 raised to support early-stage research. 2 FavoritesDecember 2015
September 2015
We are thrilled to report that last night the Ensuring Access…
Blog The Ensuring Access to Clinical Trials Act (EACT) Passes Senate, then House 2 FavoritesAugust 2015
Summit Therapeutics plc announced that its Phase 1b modified diet clinical trial of SMT C1100 for the treatment of Duchenne met its primary objective with half of the patients who received the…
Blog Summit Therapeutics Announces Phase 1B Modified Diet Clinical Trial Achieves Primary Objective In Duchenne Muscular Dystrophy 2 FavoritesJuly 2015
The first batch of presentations from PPMD’s 21st Annual Connect…
Blog PPMD's 2015 Connect Conference Resources & Recordings - Part 1 (Thursday) 1 Favorite 21st Century Cures Passes House of Representatives!21 Century Cures. First a bold concept led by two visionary…
Blog 21st Century Cures Passes House of Representatives! 2 Favorites Catabasis Pharmaceuticals Receives FDA Fast Track Designation for CAT-1004 for the Treatment of Duchenne Muscular DystrophyPPMD is excited that Catabasis has received Fast Track designation for CAT-1004 and…
Blog Catabasis Pharmaceuticals Receives FDA Fast Track Designation for CAT-1004 for the Treatment of Duchenne Muscular Dystrophy 1 FavoriteJune 2015
PPMD Listens. We have listened to patients, to families, to industry,…
Blog PPMD Listens 2 Favorites He Knows.....How I told my son that Duchenne is a fatal conditionJust your not so average Thursday afternoon for a dude with Duchenne and his momma. A conversation that needed to happen, but this momma had been struggling to find the right time to have it. …
Blog He Knows.....How I told my son that Duchenne is a fatal condition 2 FavoritesMay 2015
As many of you know, there has recently been a recall of 2 batches of…
Blog Alternative Resources for Deflazacort 1 Favorite SomaLogic Study Published: Another Piece of the PuzzleToday, SomaLogic and PPMD - together with several other Duchenne…
Blog SomaLogic Study Published: Another Piece of the Puzzle 2 FavoritesMarch 2015
I always felt a strong connection to the Duchenne community while…
Blog Recapping the FDA-NIH Dystrophin Methodology Workshop 1 Favorite Spring Forward: Bringing the MD-CARE Act to Life Despite great odds in a political climate that was stacked against us – we…
© 2023 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
